Vir Biotechnology (VIR) stock, explained like you're 5

Is Vir Biotechnology a small, medium or large cap company?

No. Vir Biotechnology is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 2 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Vir Biotechnology makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves VIR stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• Vir Biotechnology (VIR) Could Be 54% Undervalued After Gilead Collaboration (Simply Wall Street)
• Could Vir Biotechnology (VIR) Be Above Fair Value After Recent Pipeline News? (Yahoo Finance)
• Why (VIR) Price Action Is Critical for Tactical Trading (Stock Traders Daily)
• Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers (BioSpace)
• Vir Biotechnology Enters R&D Collaboration with Gilead for Three Novel PRO XTEN Dual Masked T Cell Engagers (Pharmaceutical Executive)

Key terms to know before you follow VIR

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility